Protara Therapeutics, Inc. (TARA) stock
TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.32−0.06 (-2.52%)
Close on Nov 17, 2026Market cap $137.10MP/E –Yield –
Protara Therapeutics cash
Cash and short-term investments held at the end of each period.
Protara Therapeutics's cash was $142.49M at Jun 30, 2026. For fiscal 2025 it was $155.55M, down 9.1% from the year before. Over ten years it grew 9.1% a year on average. The highest annual figure on record is $171.04M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $155.55M | -9.1% |
| FY2024 | Dec 31, 2024 | $171.04M | +157.9% |
| FY2023 | Dec 31, 2023 | $66.33M | -22.1% |
| FY2022 | Dec 31, 2022 | $85.12M | -7.5% |
| FY2021 | Dec 31, 2021 | $91.97M | -45.7% |
| FY2020 | Dec 31, 2020 | $169.39M | +2632.1% |
| FY2019 | Dec 31, 2019 | $6.20M | -71.7% |
| FY2018 | Dec 31, 2018 | $21.90M | -48.0% |
| FY2017 | Dec 31, 2017 | $42.10M | +1.9% |
| FY2016 | Dec 31, 2016 | $41.30M | -36.8% |
| FY2015 | Dec 31, 2015 | $65.30M | -21.9% |
| FY2014 | Dec 31, 2014 | $83.60M | +2893.2% |
| FY2013 | Dec 31, 2013 | $2.79M | +15.9% |
| FY2012 | Dec 31, 2012 | $2.41M | -26.3% |
| FY2011 | Dec 31, 2011 | $3.27M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $142.49M | +15.9% |
| Q1 FY2026 | Mar 31, 2026 | $135.79M | +8.5% |
| Q4 FY2025 | Dec 31, 2025 | $155.55M | -9.1% |
| Q3 FY2025 | Sep 30, 2025 | $132.67M | +61.3% |
| Q2 FY2025 | Jun 30, 2025 | $122.96M | +36.1% |
| Q1 FY2025 | Mar 31, 2025 | $125.11M | +123.5% |
| Q4 FY2024 | Dec 31, 2024 | $171.04M | +157.9% |
| Q3 FY2024 | Sep 30, 2024 | $82.24M | +10.0% |
| Q2 FY2024 | Jun 30, 2024 | $90.33M | +11.4% |
| Q1 FY2024 | Mar 31, 2024 | $55.97M | -35.9% |
| Q4 FY2023 | Dec 31, 2023 | $66.33M | -22.1% |
| Q3 FY2023 | Sep 30, 2023 | $74.78M | -23.0% |
| Q2 FY2023 | Jun 30, 2023 | $81.11M | -18.2% |
| Q1 FY2023 | Mar 31, 2023 | $87.36M | -1.1% |
| Q4 FY2022 | Dec 31, 2022 | $85.12M | -7.5% |
| Q3 FY2022 | Sep 30, 2022 | $97.06M | +3.5% |
| Q2 FY2022 | Jun 30, 2022 | $99.20M | +16.1% |
| Q1 FY2022 | Mar 31, 2022 | $88.34M | +3.8% |
| Q4 FY2021 | Dec 31, 2021 | $91.97M | -45.7% |
| Q3 FY2021 | Sep 30, 2021 | $93.76M | -43.5% |
| Q2 FY2021 | Jun 30, 2021 | $85.41M | +185.0% |
| Q1 FY2021 | Mar 31, 2021 | $85.14M | +135.7% |
| Q4 FY2020 | Dec 31, 2020 | $169.39M | +2632.1% |
| Q3 FY2020 | Sep 30, 2020 | $165.91M | +1683.9% |
| Q2 FY2020 | Jun 30, 2020 | $29.97M | +177.5% |
| Q1 FY2020 | Mar 31, 2020 | $36.12M | +115.0% |
| Q4 FY2019 | Dec 31, 2019 | $6.20M | -71.7% |
| Q3 FY2019 | Sep 30, 2019 | $9.30M | -64.5% |
| Q2 FY2019 | Jun 30, 2019 | $10.80M | -59.2% |
| Q1 FY2019 | Mar 31, 2019 | $16.80M | -54.3% |
| Q4 FY2018 | Dec 31, 2018 | $21.90M | -48.0% |
| Q3 FY2018 | Sep 30, 2018 | $26.20M | -44.7% |
| Q2 FY2018 | Jun 30, 2018 | $26.50M | -16.4% |
| Q1 FY2018 | Mar 31, 2018 | $36.80M | +7.9% |
| Q4 FY2017 | Dec 31, 2017 | $42.10M | +1.9% |
| Q3 FY2017 | Sep 30, 2017 | $47.40M | +0.9% |
| Q2 FY2017 | Jun 30, 2017 | $31.70M | – |
| Q1 FY2017 | Mar 31, 2017 | $34.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $41.30M | – |
| Q3 FY2016 | Sep 30, 2016 | $47.00M | – |
See a number that looks wrong?